Table 2.
Demographic data for hypertensive subjects and normotensive controls
| Hypertensive subjects (n=88) | |||||
|---|---|---|---|---|---|
| Normal indexed LVM (n=56) | Elevated indexed LVM (n=32) | ||||
| Controls (n=29) | Normal LV (n=41) | Concentric remodelling (n=15) | Concentric LVH (n=24) | Eccentric LVH (n=8) | |
| Age (years) | 47±13 | 45±16 | 56±12*1 | 48±12 | 56±11*2 |
| Gender (% male) | 59 | 41*3 | 60 | 71 | 88 |
| Ethnicity | |||||
| Caucasian | 93*4 | 73 | 93 | 83 | 87 |
| Black African | 3 | 0 | 0 | 9 | 13 |
| Black Caribbean | 0 | 10 | 0 | 4 | 0 |
| Oriental | 0 | 2 | 0 | 0 | 0 |
| South East Asian | 3 | 12 | 0 | 0 | 0 |
| Mixed | 0 | 2 | 7 | 4 | 0 |
| BMI (kg/m2) | 26±5*5 | 30±6 | 33±5 | 31±6 | 32±7 |
| Diabetes (%) | 0*6 | 5 | 13 | 17 | 20 |
| Heart rate (bpm) | 67±12 | 72±12 | 76±16*7 | 68±9 | 65±13 |
| Office SBP (mm Hg) | 128±12*8 | 161±26 | 175±33 | 170±30 | 172±37 |
| Office DBP (mm Hg) | 79±10*8 | 94±11 | 94±15 | 99±14 | 102±21 |
| ESH/ESC office BP grade | |||||
| Controlled (%) | … | 5 | 7 | 13 | 10 |
| High normal (%) | … | 7 | 7 | 0 | 0 |
| Grade 1 (%) | … | 39 | 13 | 25 | 10 |
| Grade 2 (%) | … | 22 | 27 | 29 | 30 |
| Grade 3 (%) | … | 22 | 47 | 33 | 50 |
| Isolated systolic HTN (%) | … | 5 | 7 | 0 | 0 |
| No. antihypertensive medications | 0*8 | 2±1 | 2±2 | 3±2*9 | 4±3*10 |
| ACEi/ARB (%) | 0*8 | 68 | 80 | 83 | 100*11 |
*1Concentric remodelling versus Normal LV: p=0.007 and Concentric remodelling versus Controls: p=0.037.
*2Eccentric LVH versus Normal LV: p=0.035.
*3Normal LV versus Concentric LVH: p=0.020 and Normal LV versus Eccentric LVH: p=0.016.
*4Controls versus Normal LV: p=0.027.
*5Controls versus Normal LV: p=0.017, Controls versus Concentric remodelling: p<0.0001, Controls versus Concentric LVH: p=0.001 and Controls versus Eccentric LVH: p=0.009.
*6Controls versus Concentric LVH: p=0.030 and Controls versus Eccentric LVH: p=0.025.
*7Concentric remodelling versus Controls: p=0.032, Concentric remodelling versus Concentric LVH: p=0.043 and Concentric remodelling versus Eccentric LVH: p=0.041.
*8Controls versus Normal LV: p<0.0001, Controls versus Concentric remodelling: p<0.0001, Controls versus Concentric LVH: p<0.0001 and Controls versus Eccentric LVH: p<0.0001.
*9Concentric LVH versus Normal LV: p=0.011.
*10Eccentric LVH versus Concentric remodelling p=0.016 and Eccentric LVH versus Normal LV: p=0.001.
*11Eccentric LVH versus Normal LV: p=0.035.
European Society of Hypertension/European Society of Cardiology (ESH/ESC) Office BP grade—Controlled SBP: 120–129 and/or DBP 80–84, High normal SBP: 130–139 mm Hg and/or DBP 85–89 mm Hg, Grade 1 SBP 140–159 and/or DBP 90–99, Grade 2 SBP 160–179 and/or DBP 100–109, Grade 3 SBP ≥180 and/or DBP ≥110, Isolated systolic hypertension SBP ≥140 mm Hg and DBP <90 mm Hg.
ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BP, blood pressure; BMI, body mass index; DBP, diastolic blood pressure; HTN, hypertension; LV, left ventricular; LVH, left ventricular hypertrophy; SBP, systolic blood pressure.